Groundbreaking Diabetes Drug Headlines Approval Bonanza

The European Union's CHMP -- the regulatory body that helps the European Medicines Agency decide whether or not a drug should be approved -- issued a slew of decisions this week, including a positive opinion for Johnson & Johnson's type 2 diabetes drug Inokana on Friday. This therapeutic, which belongs to the growing SGLT2 inhibitor drug class and already received approval in the U.S., will face competition from Bristol-Myers Squibb and AstraZeneca's drug Forxiga if it gets on the EU market. In the following video, analysts David Williamson and Max Macaluso discuss the CHMP's decision, and competitors in this space, including Merck's top-selling medication Januvia.

Nine Rock Solid Dividends
One of the best parts of owning big pharma stocks is their attractive dividends, but smart investors know the importance of diversifying -- seeking high-yielding stocks from multiple industries. The Motley Fool's special free report, "Secure Your Future With 9 Rock-Solid Dividend Stocks," outlines the Fool's favorite dependable dividend-paying stocks across all sectors. Grab your free copy by clicking here.

The relevant video segment can be found between 0:00-2:33.

The article Groundbreaking Diabetes Drug Headlines Approval Bonanza originally appeared on

David Williamson has no position in any stocks mentioned. Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Can't get enough business news?

Sign up for Finance Report by AOL and get everything from retailer news to the latest IPOs delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.